MedTrace Logo

Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome

NCT00110422 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2011-04-15

No results posted yet for this study

Summary

The purpose of this clinical research study is to learn if irbesartan is superior to hydrochlorothiazide relative to effects on insulin sensitivity and glucose metabolism in hypertensive patients with metabolic syndrome.

Conditions

Interventions

DRUG

Irbesartan

Tablets, Oral, 150 mg. titrated to 300 mg, once daily, 28 weeks.

DRUG

Hydrochlorothiazide

Tablets, Oral, 12.5 mg. titrated to 25 mg, once daily, 28 weeks.

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2007-02-28
Completion
2007-02-28

Countries

  • France
  • Germany
  • Italy
  • Norway
  • Russia
  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00110422 on ClinicalTrials.gov